Immunic, Inc. VTL Balance Sheet

Immunic, inc. (VTL)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13
Assets
Current assets:
Cash and cash equivalents
18,600	29,369	30,500	36,121	9,595	13,072	17,798	31,116	43,647	56,901	66,391	76,153	86,636	59,991	68,088	73,598	77,876	83,416	59,754	71,946	88,257	102,238	79,091	90,840	46,041	38,186
Note receivable
-	-	-	920	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	18	239	319	533	1,069	1,417	1,533	1,592	1,456	1,234	1,007	963
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	429	0	3,935	3,506
Other current assets and prepaid expenses
5,021	2,861	4,059	2,452	393	259	1,263	1,529	1,188	1,220	1,569	1,910	1,666	1,472	1,358	1,599	1,044	1,139	1,786	2,083	828	986	1,607	1,415	1,281	1,200
Total current assets
23,599	32,230	34,519	39,493	9,988	13,331	19,061	32,645	44,835	58,121	67,960	78,063	88,302	61,463	69,464	75,436	79,239	85,088	62,609	75,446	90,618	104,816	82,583	93,489	52,264	43,855
Property and equipment, net
77	80	44	43	482	40	890	2,059	2,072	2,155	2,272	2,430	2,489	2,505	2,922	3,014	3,428	3,809	4,163	4,212	4,108	3,068	2,985	3,264	3,081	2,467
Goodwill
32,970	32,970	32,970	32,970	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets, net
604	633	71	68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term assets
42	42	-	-	12	0	37	97	101	108	126	182	156	58	87	182	253	184	171	214	198	198	263	263	263	263
Total assets
57,292	65,955	67,604	72,574	10,482	13,371	19,988	34,801	47,008	60,384	70,358	80,675	90,947	64,026	72,473	78,632	82,920	89,081	66,943	79,872	94,924	108,082	85,831	97,016	55,608	46,585
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
1,432	2,423	3,718	1,462	184	1,400	1,131	1,075	893	1,049	981	1,076	1,308	780	1,193	887	885	1,221	549	920	1,128	1,153	696	1,461	1,325	1,224
Accrued expenses
3,963	3,298	3,236	1,586	1,215	416	4,552	7,185	8,701	9,141	7,167	6,147	5,085	4,656	3,357	3,439	3,788	5,271	7,380	8,852	9,591	8,875	7,530	5,806	5,496	3,253
Future purchase rights liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,472	2,600
Other current liabilities
938	1,351	82	74	34	104	8	39	72	91	86	69	57	44	80	147	143	163	190	205	227	250	272	294	340	369
Total current liabilities
6,333	7,072	7,036	3,122	1,433	1,920	5,691	8,299	9,666	10,281	8,234	7,292	6,450	5,480	4,630	4,473	4,816	6,655	8,119	9,977	10,946	10,278	8,498	7,561	8,633	7,446
Long term liabilities
Operating lease liabilities
471	520	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	41	41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146	159	200	241	283	292	279	321
Total long-term liabilities
471	520	41	41	0	0	45	49	47	59	46	46	69	100	83	12	56	101	-	-	-	-	-	-	-	-
Total liabilities
6,804	7,592	7,077	3,163	-	1,920	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and contingencies (Note 5)
6,804	7,592	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders’ equity:
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at March 31, 2020 and December 31, 2019
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.0001 par value; 130,000,000 shares authorized and 10,823,551 and 10,744,806 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
1	1	1	1	4	0	4	4	4	4	4	4	4	3	3	3	3	3	2	2	2	2	2	2	0	-
Additional paid-in capital
120,567	119,646	114,550	114,137	355,874	56	349,132	349,392	347,557	345,915	343,351	342,127	340,817	302,185	299,768	295,977	290,409	285,098	251,591	250,343	249,276	248,305	213,831	213,146	55,803	58,413
Accumulated other comprehensive loss
-1,682	-1,373	-1,804	-722	80	-819	80	80	75	78	88	90	84	83	80	80	80	80	81	88	90	89	95	95	95	96
Accumulated deficit
-68,400	-59,900	-52,000	-44,005	-346,909	-25,000	-334,964	-323,023	-310,341	-295,953	-281,365	-268,884	-256,477	-243,825	-232,091	-221,913	-212,444	-202,856	-192,996	-180,697	-165,590	-150,833	-136,878	-124,080	-	-103,166
Deficit accumulated during development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113,914	-
Total stockholders’ equity
50,488	58,363	60,527	69,411	9,049	-25,741	14,252	26,453	37,295	50,044	62,078	73,337	84,428	58,446	67,760	74,147	78,048	82,325	58,678	69,736	83,778	97,563	77,050	89,163	-58,016	-44,657
Total liabilities and stockholders’ equity
57,292	65,955	67,604	72,574	10,482	13,371	19,988	34,801	47,008	60,384	70,358	80,675	90,947	64,026	72,473	78,632	82,920	89,081	66,943	79,872	94,924	108,082	85,831	97,016	55,608	46,585
Series A-2 Convertible Preferred Stock
Preferred stock
-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series A-1 Convertible Preferred Stock
Preferred stock
-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-